更多栏目
搜索
China Regulation Tracker: Apr 2021
储旻华·4月以前
PharmaDJ

China Regulation Tracker: Apr 2021


Writer: Minhua Chu

Editor: Justin Fischer


In April, China introduced several new reform measures in the healthcare service industry.


Prescription Extensions


In China, regulations generally prohibit issuing prescriptions for longer than seven days. In 2015, the General Office of the State Council promulgated its Guidelines on Promoting the Graded Treatment System. The document suggested a pilot program for long-term prescriptions that treat chronic illnesses. The program has since been implemented in several provinces and cities in China, including Shanghai, Beijing, Shenzhen, and Zhejiang.  


Recently, the COVID-19 pandemic has accelerated the progam's implementation throughout China. On April 1 of this year, the National Health Commission (NHC) issued its Notice of Public Consultation on Long-Term Prescription Management Regulations (Draft), asking for comments from stakeholders.


According the Draft, the long-term prescriptions (generally up to four weeks) can be extended to up to 12 weeks, dependning on the nature of the disease being treated. Local health offices shall develop the list of diseases and drugs that are eligible for long-term prescriptions. Primary healthcare providers are encouraged to issue long-term presriptions as well.


Shared BMI Accounts


China’s basic medical insurance (BMI) was established in 1998 for employees and retirees in urban areas. Employers, employees and local governments all contribute to this program.


The BMI reimbursement fund has two components: a pooled fund which the employee contributes to, and an indivdual account fund, which employers contribute to. Retirees individual accounts receive contributions in fixed amounts from the pooled fund.


The pooled fund covers inpatient treatment as well as outpatient treatments for serious illnesses. The individual account reimburses normal outptient expenses. This system, however, has proven insufficient for elderly patients and people incurring high outpatient expenses. Meanwhile, younger, healthier people seldom use their individual accounts.


On April 22, the General Office of the State Council issued its Guidelines on Establishing an Outpatient Co-payment Mechanism for Employees' Basic Medical Insurance. The document calls for gradually allowing pooled funds to cover common treatments in outpatient clinics. Moreover, family members and couples will be allowed to share each others' personal accounts to help offset medical costs.


A Shift to More Online Services


The internet has been used in heathcare for nearly 20 years now, but regulations have long kept the industry from unlocking its full potential. The recent COVID-19 pandemic, however, has underscored the advantages of the using the internet in the healthcare industry, prompting the government to accelerate its application in the healthcare sector.  


New measures in the Hainan Free Trade Port support the sale of prescription drugs over internet. An electronic prescription center will be set up on Hainan in the Boao Lecheng International Medical Tourism Pilot Zone to provide the third-party information services for internet drugs sales. The Boao Lecheng International Medical Tourism Pilot Zone is a designated area on Hainan that permits the administering of treatments and devices not yet licensed in China but have been approved overseas.


According to this arrangement, all prescription drugs that are marketed in China can be sold over the internet with no futher licensing requirements.


Additionally, in an effort to improve healthcare services in Shanghai, new regulations now support using the internet to share lab and imaging results and other medical data. China's BMI will also cover the cost of such services.


文章关键字: China Regulation Tracker COVID-19 Prescription Extensions BMI basic medical insurance Online Services National Health Commission (NHC) Guidelines on Promoting the Graded Treatment System.
1425
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明